ReNeuron Group PLC (LON:RENE) said it has appointed Stefano Pluchino as its chief scientific officer with immediate effect.
The developer of cell-based therapies said Pluchino will join the company on a part-time basis and bring “a wealth of knowledge of cell and gene therapy”.
READ: ReNeuron unveils new collaborations, data findings on exosome technology platform
Pluchino has been a reader in regenerative neuroimmunology and honorary consultant at the University of Cambridge since 2010 and has published over 120 peer-reviewed papers including several in top scientific journals including Nature, Cell and Cell Stem Cell. The firm added that Pluchino is “internationally recognised as a leader and pioneer in the field of regenerative neuroimmunology”.
"We are delighted to welcome Dr Pluchino to ReNeuron. His extensive experience of cell and gene therapy as well as deep knowledge in the exosomes field will be invaluable to us in what is an incredibly exciting and progressive time. Dr Pluchino's work is widely recognised, and we look forward to working alongside him, as ReNeuron continues to grow and develop its pipeline", ReNeuron chief executive Olav Hellebø said in a statement.